Insulin Calculator Cleared; Twice-Rejected Diabetes Drug; Ozempic for Alcohol Use?

— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, �鶹��ý August 29, 2023

Endo Break over a computer rendering of a man with illustrated body organs.

The FDA cleared the BlueStar, featuring a continuous glucose monitoring-informed bolus insulin dose calculator, developer Welldoc announced.

The agency also cleared Roche's -- a tubing-free pump for insulin users.

Several phased-out flame retardants and were found in the breast milk of mothers. (NPR)

Third times the charm? An FDA advisory committee is convening in a few weeks to once again discuss Intarcia's after it was already rejected twice. (Endpoints News)

Certain were found to be "strongly prognostic" in patients with type 2 diabetes and albuminuria, said researchers in Circulation.

The risk of was similar for those who received group versus individual prenatal care. (JAMA Network Open)

Some individuals say semaglutide (Ozempic, Wegovy) has . (NPR)

Europe will continue to have through September, the European Medicines Agency said. (Reuters)

Researchers at University of California San Diego received a $2 million grant to study .

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.